"RNAi Roundtable: ALN-HBV in Development for the Treatment of Hepatitis B Virus (HBV) Infection", 29 July 2014 (2014-07-29), XP055246909, Retrieved from the Internet <URL:http://www.alnylam.com/web/assets/Roundtable_ALN-HBV_072914.pdf> (B1)

ANONYMOUS: "History of Changes for Study: NCT03672188", 26 November 2018 (2018-11-26), XP055675500, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03672188?V_2=View#StudyPageTop> [retrieved on 20200311] (B1)

ANONYMOUS: "Pipeline | hepatitis B | influenza A | HIV | tuberculosis | Vir Biotechnology", 9 September 2019 (2019-09-09), XP055675497, Retrieved from the Internet <URL:https://web.archive.org/web/20190909074713/https://www.vir.bio/pipeline/> [retrieved on 20200311] (B1)

ANONYMOUS: "Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218", 26 November 2018 (2018-11-26), XP055675766, Retrieved from the Internet <URL:https://www.altapartners.com/vir-biotechnology-and-alnylam-pharmaceuticals-initiate-phase-1-2-study-of-vir-2218> [retrieved on 20200311] (B1)

ANONYMOUS: "Vir Biotechnology, Inc. 40th Annual Cowen Healthcare Conference March 3, 2020", 3 March 2020 (2020-03-03), pages 2138 - 2159, XP055675498, Retrieved from the Internet <URL:https://investors.vir.bio/static-files/29ef45cd-def1-402f-b2fd-d9fb2197fe08> [retrieved on 20200311], DOI: 10.1287/mnsc.2013.1879 (B1)

WO-A2-2018/027106 (B1)

WO-A1-2011/047312 (B1)

WO-A1-2016/077321 (B1)

WO-A1-2017/059878 (B1)

WO-A1-2018/195165 (B1)

WO-A2-2017/027350 (B1)

US-A1- 2015 166 637 (B1)